

Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-06-14 | 138 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$2499.00
- Five User Licence \$3499.00
- Enterprisewide License \$4499.00

Report description:

The global generic injectables market size reached US\$ 43.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 70.4 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.

A generic injectable is a drug formulated with the same active pharmaceutical ingredient as its branded counterpart in strength, dosage form, safety, performance, quality, intended use, side effects, and route of administration. It is as safe and effective as the innovator drug and is consequently used for administering the medication rapidly into the body. It facilitates the easy absorption of medicines in liquid form, which helps reduce the frequency of dosage administration without affecting the efficacy of the treatment. Besides this, it is cost-effective and does not require investment in testing, promotional activities, and research and development (R&D) compared to its branded counterparts. As a result, generic injectables are extensively utilized in treating cancer, diabetes, osteoporosis, osteoarthritis, rheumatoid arthritis, and respiratory, neurological, and cardiovascular disorders.

Generic Injectables Market Trends:

The growing global geriatric population, which is more susceptible to several chronic medical ailments, such as diabetes, cancer, and cardiovascular diseases, represents one of the key factors driving the demand for generic injectables worldwide. In addition, the rising occurrence of lifestyle disorders due to hectic schedules, changing dietary patterns, and sedentary lifestyles of individuals are positively influencing the market. Apart from this, initiatives undertaken by governing authorities of numerous countries to support key manufacturers and sellers are offering lucrative growth opportunities to manufacturers. This, along with the widespread adoption of advanced technologies in the manufacturing process of generic injectables, is propelling the market growth. Furthermore, the expansion of offline pharmacies, along with the easy availability of generic injectables via online pharmacies, is offering a favorable market outlook. The emerging trend of online shopping offers consumers a wide range of products, free doorstep delivery, exciting deals and discounts, and secured payment methods is anticipated to drive the market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global generic injectables market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on therapeutic area, container, and distribution channel.

Breakup by Therapeutic Area:

- Oncology
- Anaesthesia
- Anti-infectives
- Parenteral Nutrition
- Cardiovascular

The oncology segment currently dominates the market due to the increasing number of cancer patients.

Breakup by Container:

- Vials
- Ampoules
- Premix
- Prefilled Syringes

On the basis of the container, the market has been segmented into vials, ampoules, premix, and prefilled syringes.

Breakup by Distribution Channel:

- Hospitals
- Retail Pharmacy

Hospitals hold the largest market share due to the increasing cases of chronic medical disorders and the growing expansion of hospitals across the globe.

Regional Insights:

- Europe
- North America
- Asia
- Latin America
- Middle East and Africa

North America enjoys the leading position in the market due to the existence of various leading manufacturers in the country.

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being

Hospira (Pfizer)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Fresenius Kabi
Hikma
Sandoz (Novartis)
Sagent
Sanofi
Baxter

This report provides a deep insight into the global generic injectables industry covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. The report also provides a comprehensive analysis for setting up a generic injectables manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global generic injectables industry in any manner.

Key Questions Answered in This Report

1. What was the size of the global generic injectables market in 2022?
2. What is the expected growth rate of the global generic injectables market during 2023-2028?
3. What has been the impact of COVID-19 on the global generic injectables market?
4. What are the key factors driving the global generic injectables market?
5. What is the breakup of the global generic injectables market based on the therapeutic area?
6. What is the breakup of the global generic injectables market based on the distribution channel?
7. What are the key regions in the global generic injectables market?
8. Who are the key players/companies in the global generic injectables market?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
 - 2.1 Objectives of the Study
 - 2.2 Stakeholders
 - 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
 - 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
 - 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
 - 4.1 Overview
 - 4.2 Key Industry Trends
- 5 Global Generic Drug Market
 - 5.1 Market Overview
 - 5.2 Market Performance
 - 5.3 Market Breakup by Region
 - 5.4 Market Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.5 Major Players
- 6 Global Generic Drug Delivery Market
 - 6.1 Oral
 - 6.2 Injectables
 - 6.3 Dermal/Topical
 - 6.4 Inhalers
- 7 Global Generic Injectables Market
 - 7.1 Market Overview
 - 7.2 Market Performance
 - 7.3 Impact of COVID-19
 - 7.4 Market Breakup by Region
 - 7.5 Market Breakup by Therapeutic Area
 - 7.6 Market Breakup by Container
 - 7.7 Market Breakup by Distribution Channel
 - 7.8 Market Forecast
 - 7.9 SWOT Analysis
 - 7.9.1 Overview
 - 7.9.2 Strengths
 - 7.9.3 Weaknesses
 - 7.9.4 Opportunities
 - 7.9.5 Threats
 - 7.10 Value Chain Analysis
 - 7.11 Porter's Five Forces Analysis
 - 7.11.1 Overview
 - 7.11.2 Bargaining Power of Buyers
 - 7.11.3 Bargaining Power of Suppliers
 - 7.11.4 Degree of Competition
 - 7.11.5 Threat of New Entrants
 - 7.11.6 Threat of Substitutes
 - 7.12 Key Market Drivers and Success Factors
- 8 Global Generic Injectables Market: Performance of Key Regions
 - 8.1 North America
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
 - 8.2 Europe
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
 - 8.3 Asia
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast
 - 8.4 Latin America
 - 8.4.1 Market Trends
 - 8.4.2 Market Forecast
 - 8.5 Middle East and Africa
 - 8.5.1 Market Trends
 - 8.5.2 Market Forecast
- 9 Market by Therapeutic Area

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1 Oncology
 - 9.1.1 Market Trends
 - 9.1.2 Market Forecast
- 9.2 Anaesthesia
 - 9.2.1 Market Trends
 - 9.2.2 Market Forecast
- 9.3 Anti-infectives
 - 9.3.1 Market Trends
 - 9.3.2 Market Forecast
- 9.4 Parenteral Nutrition
 - 9.4.1 Market Trends
 - 9.4.2 Market Forecast
- 9.5 Cardiovascular
 - 9.5.1 Market Trends
 - 9.5.2 Market Forecast
- 10 Market by Container
 - 10.1 Vials
 - 10.1.1 Market Trends
 - 10.1.2 Market Forecast
 - 10.2 Ampoules
 - 10.2.1 Market Trends
 - 10.2.2 Market Forecast
 - 10.3 Premix
 - 10.3.1 Market Trends
 - 10.3.2 Market Forecast
 - 10.4 Prefilled Syringes
 - 10.4.1 Market Trends
 - 10.4.2 Market Forecast
- 11 Market by Distribution Channel
 - 11.1 Hospitals
 - 11.1.1 Market Trends
 - 11.1.2 Market Forecast
 - 11.2 Retail Pharmacy
 - 11.2.1 Market Trends
 - 11.2.2 Market Forecast
- 12 Global Generic Injectables Market: Competitive Landscape
 - 12.1 Market Structure
 - 12.2 Market Breakup by Key Players
- 13 Generic Injectables Manufacturing Process
 - 13.1 Product Overview
 - 13.2 Detailed Process Flow (Injectables)
 - 13.3 Various Types of Unit Operations Involved
 - 13.4 Mass Balance and Raw Material Requirements
- 14 Project Details, Requirements and Costs Involved
 - 14.1 Land Requirements and Expenditures
 - 14.2 Construction Requirements and Expenditures
 - 14.3 Plant Machinery

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.4 Machinery Pictures
- 14.5 Raw Material Requirements and Expenditures
- 14.6 Packaging Requirements and Expenditures
- 14.7 Transportation Requirements and Expenditures
- 14.8 Utility Requirements and Expenditures
- 14.9 Manpower Requirements and Expenditures
- 14.10 Other Capital Investments
- 15 Loans and Financial Assistance
- 16 Project Economics
 - 16.1 Capital Cost of the Project
 - 16.2 Techno-Economic Parameters
 - 16.3 Product Pricing and Margins Across Various Levels of the Supply Chain
 - 16.4 Taxation and Depreciation
 - 16.5 Income Projections
 - 16.6 Expenditure Projections
 - 16.7 Financial Analysis
 - 16.8 Profit Analysis
- 17 Key Player Profiles
 - 17.1 Hospira (Pfizer)
 - 17.1.1 Company Overview
 - 17.1.2 Product Portfolio
 - 17.1.3 Financials
 - 17.1.4 SWOT Analysis
 - 17.2 Fresenius Kabi
 - 17.2.1 Company Overview
 - 17.2.2 Product Portfolio
 - 17.2.3 Financials
 - 17.2.4 SWOT Analysis
 - 17.3 Hikma
 - 17.3.1 Company Overview
 - 17.3.2 Product Portfolio
 - 17.3.3 Financials
 - 17.3.4 SWOT Analysis
 - 17.4 Sandoz (Novartis)
 - 17.4.1 Company Overview
 - 17.4.2 Product Portfolio
 - 17.4.3 Financials
 - 17.4.4 SWOT Analysis
 - 17.5 Sagent
 - 17.5.1 Company Overview
 - 17.5.2 Product Portfolio
 - 17.5.3 Financials
 - 17.5.4 SWOT Analysis
 - 17.6 Sanofi
 - 17.6.1 Company Overview
 - 17.6.2 Product Portfolio
 - 17.6.3 Financials

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.6.4 SWOT Analysis

17.7 Baxter

17.7.1 Company Overview

17.7.2 Product Portfolio

17.7.3 Financials

17.7.4 SWOT Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-06-14 | 138 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$2499.00
	Five User Licence	\$3499.00
	Enterprisewide License	\$4499.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-06"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com